Corium International Inc (CORI) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Corium International Inc (NASDAQ:CORI) in a research note published on Friday, April 14th. They currently have a $10.00 target price on the biopharmaceutical company’s stock.

Several other brokerages have also recently weighed in on CORI. Cantor Fitzgerald initiated coverage on Corium International in a research note on Friday, December 16th. They set an overweight rating and a $10.00 price objective on the stock. FBR & Co set a $18.00 target price on Corium International and gave the company a buy rating in a research note on Wednesday, January 18th. Zacks Investment Research cut Corium International from a hold rating to a sell rating in a research note on Tuesday, January 24th. Leerink Swann reiterated a buy rating on shares of Corium International in a report on Wednesday, January 4th. Finally, Jefferies Group LLC reiterated a buy rating and issued a $8.00 price target on shares of Corium International in a report on Friday, March 17th. Six research analysts have rated the stock with a buy rating, Corium International currently has a consensus rating of Buy and an average price target of $10.71.

Corium International (NASDAQ:CORI) traded up 0.217% during midday trading on Friday, hitting $6.915. The stock had a trading volume of 2,131,280 shares. The company’s market cap is $202.14 million. The firm’s 50-day moving average price is $4.74 and its 200 day moving average price is $4.30. Corium International has a 12 month low of $2.67 and a 12 month high of $8.33.

Corium International (NASDAQ:CORI) last issued its quarterly earnings data on Thursday, May 11th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.05. Corium International had a negative return on equity of 359.24% and a negative net margin of 116.26%. The company had revenue of $7.35 million for the quarter, compared to the consensus estimate of $6.05 million. On average, analysts expect that Corium International will post ($1.69) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.com-unik.info/2017/05/19/needham-company-llc-reiterates-buy-rating-for-corium-international-inc-cori-updated-updated-updated.html.

Several institutional investors have recently added to or reduced their stakes in CORI. Perceptive Advisors LLC purchased a new position in Corium International during the first quarter valued at about $11,096,000. AWM Investment Company Inc. increased its position in Corium International by 1,125.9% in the first quarter. AWM Investment Company Inc. now owns 2,451,700 shares of the biopharmaceutical company’s stock valued at $10,248,000 after buying an additional 2,251,700 shares during the last quarter. Senzar Asset Management LLC purchased a new position in Corium International during the fourth quarter valued at about $6,402,000. Broadfin Capital LLC increased its stake in shares of Corium International by 45.2% in the first quarter. Broadfin Capital LLC now owns 2,787,121 shares of the biopharmaceutical company’s stock valued at $11,650,000 after buying an additional 867,400 shares in the last quarter. Finally, Royce & Associates LP increased its stake in shares of Corium International by 208.4% in the first quarter. Royce & Associates LP now owns 548,464 shares of the biopharmaceutical company’s stock valued at $2,293,000 after buying an additional 370,600 shares in the last quarter. 67.75% of the stock is currently owned by hedge funds and other institutional investors.

About Corium International

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

5 Day Chart for NASDAQ:CORI

What are top analysts saying about Corium International Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Corium International Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit